KR102444494B1 - 비정상적 세포 성장의 치료를 위한 조성물 및 방법 - Google Patents

비정상적 세포 성장의 치료를 위한 조성물 및 방법 Download PDF

Info

Publication number
KR102444494B1
KR102444494B1 KR1020167021370A KR20167021370A KR102444494B1 KR 102444494 B1 KR102444494 B1 KR 102444494B1 KR 1020167021370 A KR1020167021370 A KR 1020167021370A KR 20167021370 A KR20167021370 A KR 20167021370A KR 102444494 B1 KR102444494 B1 KR 102444494B1
Authority
KR
South Korea
Prior art keywords
composition
pharmaceutically acceptable
acceptable salt
delete delete
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167021370A
Other languages
English (en)
Korean (ko)
Other versions
KR20160104725A (ko
Inventor
마헤쉬 파드발
폴 오콰비 칸사
Original Assignee
베라스템, 인코포레이티드
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베라스템, 인코포레이티드, 화이자 인코포레이티드 filed Critical 베라스템, 인코포레이티드
Priority to KR1020227031505A priority Critical patent/KR20220130251A/ko
Publication of KR20160104725A publication Critical patent/KR20160104725A/ko
Application granted granted Critical
Publication of KR102444494B1 publication Critical patent/KR102444494B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
KR1020167021370A 2014-01-09 2015-01-09 비정상적 세포 성장의 치료를 위한 조성물 및 방법 Active KR102444494B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227031505A KR20220130251A (ko) 2014-01-09 2015-01-09 비정상적 세포 성장의 치료를 위한 조성물 및 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461925467P 2014-01-09 2014-01-09
US61/925,467 2014-01-09
PCT/US2015/010810 WO2015106096A1 (en) 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227031505A Division KR20220130251A (ko) 2014-01-09 2015-01-09 비정상적 세포 성장의 치료를 위한 조성물 및 방법

Publications (2)

Publication Number Publication Date
KR20160104725A KR20160104725A (ko) 2016-09-05
KR102444494B1 true KR102444494B1 (ko) 2022-09-20

Family

ID=52434976

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020167021370A Active KR102444494B1 (ko) 2014-01-09 2015-01-09 비정상적 세포 성장의 치료를 위한 조성물 및 방법
KR1020247035735A Pending KR20240159639A (ko) 2014-01-09 2015-01-09 비정상적 세포 성장의 치료를 위한 조성물 및 방법
KR1020227031505A Ceased KR20220130251A (ko) 2014-01-09 2015-01-09 비정상적 세포 성장의 치료를 위한 조성물 및 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247035735A Pending KR20240159639A (ko) 2014-01-09 2015-01-09 비정상적 세포 성장의 치료를 위한 조성물 및 방법
KR1020227031505A Ceased KR20220130251A (ko) 2014-01-09 2015-01-09 비정상적 세포 성장의 치료를 위한 조성물 및 방법

Country Status (15)

Country Link
US (3) US20150190346A1 (https=)
EP (2) EP3091981B1 (https=)
JP (5) JP6647204B2 (https=)
KR (3) KR102444494B1 (https=)
CN (3) CN115708827A (https=)
AU (4) AU2015204597B2 (https=)
BR (1) BR112016016021B1 (https=)
CA (1) CA2936283C (https=)
DK (1) DK3091981T3 (https=)
ES (1) ES2870562T3 (https=)
IL (2) IL246667B (https=)
MX (2) MX384259B (https=)
NZ (2) NZ760233A (https=)
SG (2) SG11201605588YA (https=)
WO (1) WO2015106096A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102942294B1 (ko) * 2018-05-15 2026-03-23 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 소분자 이지에프알 억제제를 포함하는 약학 조성물 및 그의 제조 방법
JP2022547358A (ja) 2019-09-13 2022-11-14 ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル 治療組成物、組み合わせ、及び使用方法
JP2021155415A (ja) * 2020-03-27 2021-10-07 ファイザー・インク ２−［（４−｛６−［（４−シアノ−２−フルオロベンジル）オキシ］ピリジン−２−イル｝ピペリジン−１−イル）メチル］−１−［（２ｓ）−オキセタン−２−イルメチル］−１ｈ−ベンゾイミダゾール−６−カルボン酸またはその薬学的な塩を用いた２型糖尿病、または肥満、または過体重の治療
MX2022013344A (es) * 2020-04-24 2022-11-30 Dr Falk Pharma Gmbh Formulacion sistemica de un derivado de la piridinona para las enfermedades relacionadas con la tg2.
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2024037498A1 (zh) * 2022-08-15 2024-02-22 海创药业股份有限公司 一种治疗卵巢癌的联合用药物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008129380A1 (en) * 2007-04-18 2008-10-30 Pfizer Products Inc. Sulfonyl amide derivatives for the treatment of abnormal cell growth

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2287971T3 (es) * 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
BRPI0413363A (pt) * 2003-08-04 2006-10-10 Pfizer Prod Inc formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
WO2006061712A2 (en) * 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
HRP20180328T1 (hr) * 2008-08-13 2018-04-20 Vertex Pharmaceuticals Inc. FARMACEUTSKI PRIPRAVAK N-[2,4-bis(1,1-DIMETILETIL)-5-HIDROKSIFENIL]-1,4-DIHIDRO-4-OKSOKINOLIN-3-KARBOKSAMIDA I NJEGOVO DAVANJE
WO2011112922A2 (en) * 2010-03-11 2011-09-15 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
CA2808501A1 (en) * 2010-08-23 2012-03-01 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
US8591944B2 (en) * 2011-03-08 2013-11-26 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
EP2572731A1 (en) * 2011-09-26 2013-03-27 Abbott GmbH & Co. KG Formulations based on solid dispersions
WO2015120289A1 (en) * 2014-02-07 2015-08-13 Verastem, Inc. Methods and compositions for treating abnormal cell growth
US10532056B2 (en) * 2015-06-29 2020-01-14 Verastem, Inc. Therapeutic compositions, combinations, and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008129380A1 (en) * 2007-04-18 2008-10-30 Pfizer Products Inc. Sulfonyl amide derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
US20200038331A1 (en) 2020-02-06
NZ721934A (en) 2022-04-29
AU2025204843A1 (en) 2025-07-17
AU2015204597A1 (en) 2016-07-21
CA2936283A1 (en) 2015-07-16
MX2016009056A (es) 2017-01-23
AU2020210153A1 (en) 2020-08-13
JP2017502062A (ja) 2017-01-19
IL246667B (en) 2022-05-01
US20150190346A1 (en) 2015-07-09
CN115708827A (zh) 2023-02-24
MX2021008225A (es) 2021-08-11
AU2015204597B2 (en) 2020-04-30
IL246667A0 (en) 2016-08-31
BR112016016021A8 (pt) 2018-04-17
JP2025084892A (ja) 2025-06-03
MX384259B (es) 2025-03-14
AU2022256144B2 (en) 2025-04-03
NZ760233A (en) 2022-04-29
AU2022256144A1 (en) 2022-11-24
DK3091981T3 (da) 2021-05-31
CA2936283C (en) 2023-02-28
SG10201805890QA (en) 2018-08-30
BR112016016021B1 (pt) 2023-01-10
KR20220130251A (ko) 2022-09-26
SG11201605588YA (en) 2016-08-30
CN119868364A (zh) 2025-04-25
CN106102744A (zh) 2016-11-09
AU2020210153B2 (en) 2022-07-21
KR20240159639A (ko) 2024-11-05
EP3900726A1 (en) 2021-10-27
BR112016016021A2 (pt) 2017-09-19
ES2870562T3 (es) 2021-10-27
IL292054A (en) 2022-06-01
JP6647204B2 (ja) 2020-02-14
WO2015106096A1 (en) 2015-07-16
KR20160104725A (ko) 2016-09-05
JP2020007355A (ja) 2020-01-16
US20230104303A1 (en) 2023-04-06
JP2023065568A (ja) 2023-05-12
JP2022001587A (ja) 2022-01-06
EP3091981B1 (en) 2021-03-10
EP3091981A1 (en) 2016-11-16

Similar Documents

Publication Publication Date Title
AU2022256144B2 (en) Compositions and methods for treatment of abnormal cell growth
CN115243681B (zh) 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
JP5835883B2 (ja) 被覆錠剤製剤
JP2021501142A (ja) キナーゼを調節する化合物の製剤
TW201210591A (en) Oral dosage forms of bendamustine and therapeutic use thereof
JP2024542248A (ja) Ｆｇｆｒ阻害剤とｋｒａｓ阻害剤を含む併用療法
EP3052130B1 (en) Pharmaceutical composition comprising capecitabine and cyclophosphamide
KR101587140B1 (ko) 위장관 질환 치료용 모사프리드 구연산염 미니정제 함유 서방성 캡슐 제제 및 이의 제조 방법
HK40062771A (en) Compositions and methods for treatment of abnormal cell growth
HK1230956B (en) Compositions and methods for treatment of abnormal cell growth
HK1230942A1 (en) Compositions and methods for treatment of abnormal cell growth
RU2586290C1 (ru) Твердая лекарственная форма прокарбазина немедленного высвобождения и способ ее получения
KR20260022394A (ko) 에스트로겐 수용체 분해제의 고형 경구제
KR20180112066A (ko) 피롤로-융합된 6-원의 헤테로시클릭 화합물을 포함하는 약학적 조성물
BR122024022942A2 (pt) Composições farmaceuticamente aceitáveis para administração oral, comprimidos farmaceuticamente aceitáveis, usos relacionados, processo para a preparação de uma dispersão sólida, dispersão sólida e kit compreendendo a composição

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4